Last BACE bombs: Eisai, Biogen give up on elenbecestatThe final BACE inhibitor in clinical testing for Alzheimer’s disease – Eisai and Biogen’s elenbecestat – has been Share XLast BACE bombs: Eisai, Biogen give up on elenbecestathttps://pharmaphorum.com/news/last-bace-bombs-eisai-biogen-give-up-on-elenbecestat/
Listening to the patient voice: Why developing new dementia treatments is everyone’s jobDeveloping life-changing treatments for dementia is a team effort that takes commitment from all involved, from charities and Share XListening to the patient voice: Why developing new dementia treatments is everyone’s jobhttps://pharmaphorum.com/views-and-analysis/listening-to-the-patient-voice-why-developing-new-dementia-treatments-is-everyones-job/
Pilot study suggests smart devices could help spot early dementiaA preliminary study run by Eli Lilly, Apple and Evidation has suggested that connected smart devices can detect Share XPilot study suggests smart devices could help spot early dementiahttps://pharmaphorum.com/news/pilot-study-suggests-smart-devices-could-help-spot-early-dementia/
AC Immune trials Alzheimer’s vaccineSwitzerland’s AC Immune biopharma has begun mid-stage trials of a vaccine against Alzheimer’s disease and Abeta-related cognitive decline Share XAC Immune trials Alzheimer’s vaccinehttps://pharmaphorum.com/news/ac-immune-trials-alzheimers-vaccine/
Philanthropists donate $30m towards finding Alzheimer’s cureA coalition of philanthropists has announced they are donating more than $30 million in a drive to combat Share XPhilanthropists donate $30m towards finding Alzheimer’s curehttps://pharmaphorum.com/news/philanthropists-donate-30m-towards-finding-alzheimers-cure/
Hope for Alzheimer’s treatment after promising study resultsBiogen and Eisai said their latest clinical study confirmed the amyloid hypothesis and might lead to the first Share XHope for Alzheimer’s treatment after promising study resultshttps://pharmaphorum.com/news/alzheimers-disease-promising-study/
Eisai accelerates dementia drug discovery researchEisai is launching a special dementia discovery centre to boost development of next-generation medicines targeting forms of the Share XEisai accelerates dementia drug discovery researchhttps://pharmaphorum.com/news/eisai-dementia-drug-research/
AstraZeneca and Lilly’s Alzheimer’s drug fails trialThe battle to develop a drug to treat Alzheimer’s disease has been dealt a blow following disappointing phase Share XAstraZeneca and Lilly’s Alzheimer’s drug fails trialhttps://pharmaphorum.com/news/astrazeneca-lillys-alzheimers-drug/
New HQ to be flagship for UK’s dementia researchThe UK is investing more in its ‘Grand Challenge’ to tackle dementia, with a £40 million investment in Share XNew HQ to be flagship for UK’s dementia researchhttps://pharmaphorum.com/news/new-hq-flagship-uks-dementia-research/
